The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials

DOI10.1016/j.jspi.2007.06.005zbMath1138.62079OpenAlexW2062420969WikidataQ59901647 ScholiaQ59901647MaRDI QIDQ2475730

Ariel Alonso, Marc Buyse, Pryseley Assam, Tomasz Burzykowski, Abel Tilahun, Geert Molenberghs

Publication date: 11 March 2008

Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)

Full work available at URL: http://hdl.handle.net/1942/8005

zbMATH Keywords

hierarchical modelmeta-analysislikelihood reduction factorsurrogate threshold effectinformation-theoretic unification

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Statistical aspects of information-theoretic topics (62B10)

Related Items (3)

Center-within-trial versus trial-level evaluation of surrogate endpoints ⋮ Comparing Biomarkers as Principal Surrogate Endpoints ⋮ An information-theoretic approach to surrogate-marker evaluation with failure time endpoints

Cites Work

• Unnamed Item
• Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
• A Mathematical Theory of Communication
• Choice of units of analysis and modeling strategies in multilevel hierarchical models
• The evaluation of surrogate endpoints.
• Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
• Survival models for heterogeneous populations derived from stable distributions
• A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence
• Inferences on the Association Parameter in Copula Models for Bivariate Survival Data
• Simplified hierarchical linear models for the evaluation of surrogate endpoints
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• On meta-analytic assessment of surrogate outcomes
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• General class of covariance structures for two or more repeated factors in longitudinal data analysis
• Modelling Progression of CD4-Lymphocyte Count and Its Relationship to Survival Time
• Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes
• Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements
• Surrogate Marker Evaluation from an Information Theory Perspective
• Linear mixed models for longitudinal data

This page was built for publication: The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials